comparemela.com

Latest Breaking News On - Spiegel lab - Page 2 : comparemela.com

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University

Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs

Published: Jan 07, 2021   NEW HAVEN, Conn., Jan. 7, 2021 /PRNewswire/  Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the Company or Biohaven ) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. ( Kleo ) that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.

citybizlist : New York : Biohaven Acquires Kleo Pharmaceuticals

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the acquisition of the remaining 58% interest of Kleo Pharmaceuticals, Inc. that it did not previously own and the execution of an exclusive license agreement with Yale University for a novel extracellular degrader technology licensed from the Spiegel Lab. In connection with these two transactions, Biohaven assumed Kleo s laboratory facilities located in Science Park in New Haven, Connecticut and formed Biohaven Labs to serve as the integrated chemistry and discovery research arm of Biohaven. Biohaven Labs will continue several existing Kleo discovery partnerships, including with the Bill and Melinda Gates Foundation for the development of a Hyperimmune Globulin Mimic (HGM) for COVID-19 and PeptiDream for the development of immuno-oncology therapeutics.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.